Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Oncology·MeSH: Recurrence

Prevalence

3.2 / 100K

Incidence

3.2 / 100K/yr

0 drugs in development·0 companies·2 clinical trials

Frequently asked questions

How many clinical trials target Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype?

There are 2 clinical trials targeting Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype tracked by BioSniper.

What is the prevalence of Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype?

The estimated prevalence of Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype is approximately 3.2 per 100,000 population.

Deep-dive into Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype — Drugs in Development & Clinical Trials | BioSniper